Antitumor properties of mononuclear cells activated by combined treatment with oxidizing mitogens and interleukin-2: basic and clinical studies.
Novogrodsky
A
A
Stenzel
K H
KH
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005692:Galactose Oxidase / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy; D007376:Interleukin-2 / Q000494:pharmacology*; D007680:Kidney Neoplasms / Q000628:therapy*; D007694:Killer Cells, Natural / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology*; D008213:Lymphocyte Activation; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology*; D009439:Neuraminidase / Q000627:therapeutic use; D010084:Oxidation-Reduction; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D008934:Mitogens; D005692:Galactose Oxidase; D009439:Neuraminidase